FutureCure Health has completed a Rs 104 crore funding round to expand access to the diagnosis and treatment of vertigo and balance disorders in India and overseas. Vertigo and balance disorders affect nearly six crore people in India, many of whom are misdiagnosed or treated with symptom-suppressing medication instead of therapy targeting the underlying condition.
The funding round was led by Carnelian Asset Management LLP, with participation from other investors. The raise follows an earlier USD 4 million funding round in 2022 backed by Kotak Alternate Asset Management, RVCF Ventures, and Unicorn India Ventures.
FutureCure Health operates NeuroEquilibrium, its wholly owned subsidiary, which functions as a chain of vertigo and dizziness diagnostic and rehabilitation clinics. NeuroEquilibrium focuses on identifying the cause of vertigo, whether related to the inner ear, the brain, or balance pathways, to enable targeted treatment. The company works with hospitals, ENT clinics, and neurology centres and operates over 300 clinics in India and 16 other countries. It has supported diagnosis and treatment for more than 150,000 patients.
“This funding has reinforced our conviction that globally relevant healthcare technologies can be built in India. As we scale NeuroEquilibrium across hospitals in India and globally and expand into chronic lifestyle diseases such as migraine and diabetes, our focus is on using technology to bridge the shortage of specialist doctors. Precise, scalable diagnostics can democratise super-speciality healthcare and act as a true force multiplier for better outcomes,” said Rajneesh Bhandari, Founder, FutureCure Health.
Dr Anita Bhandari, Founder, FutureCure Health, said, “Vertigo/dizziness is often misdiagnosed, leaving patients untreated for years. Our work with 150,000+ patients proves that accurate diagnosis changes outcomes. This funding will help us take specialised vertigo care global.”